Silexion Therapeutics Corp
- Nasdaq
- SLXN, SLXNW
- CIK
- 2022416
- Based in
- Israel
- Incorporated in
- Cayman Islands
- Fiscal year ends
- December 31
- SEC filer category
- Emerging growth company
- Formerly
- Biomotion Sciences
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 |
|---|---|---|
| Operating income | −$11.6M | −$12.6M |
| Net income | −$11.9M | −$16.5M |
| Diluted EPS | $8.96 | $394.94 |
| Cash from operations | −$10.8M | −$8.40M |
| Total assets | $7.21M | $2.86M |
| Shareholders’ equity | $2.60M | −$3.99M |
From the company’s annual reports to the SEC. Each year links to its report.
Insiders 10
| Name | Role | As of |
|---|---|---|
| Hadar Ilan | Chairman and CEO, Director | |
| Horenshtein Hadar Mirit | CFO and Secretary | |
| Shirvan Mitchell | CSO and CDO | |
| Noy Shlomo | Director | |
| Abramov Dror Yosef | Director | |
| Alon Ruth | Director |
Large shareholders 3
| Name | Stake | As of |
|---|---|---|
| Moringa Sponsor, LP | 17.7% | |
| Intracoastal Capital, LLC | 5% | |
| Lind Global Fund III LP | 5% |
Financials 11
- 10-Q Quarterly Report for period ending Sep 30, 2026
- 10-Q Quarterly Report for period ending Jun 30, 2026
- 10-K/A Annual Report for period ending Dec 31, 2025
- 10-Q Quarterly Report for period ending Mar 31, 2026
- 10-K Annual Report for period ending Dec 31, 2025
- 10-Q Quarterly Report for period ending Sep 30, 2025
- 10-Q Quarterly Report for period ending Jun 30, 2025
- 10-Q Quarterly Report for period ending Mar 31, 2025
- 10-K Annual Report for period ending Dec 31, 2024
- 10-Q Quarterly Report for period ending Sep 30, 2024
News 87
- 8-K Other events
- 8-K Financial results
- 8-K Change to shareholder rights; Charter or bylaw change; Other events
- 8-K Other events
- 8-K Charter or bylaw change; Shareholder vote results
- 8-K Regulation FD disclosure
- 8-K Material agreement; Unregistered share sale; Other events
- 8-K Regulation FD disclosure
- 8-K Delisting notice
- 8-K Shareholder vote results
Ownership 53
- SCHEDULE 13D/A Major shareholder report
- SCHEDULE 13D/A Major shareholder report
- SCHEDULE 13G Major shareholder report (passive investor)
- SCHEDULE 13G/A Major shareholder report (passive investor)
- SCHEDULE 13D/A Major shareholder report
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- SCHEDULE 13D/A Major shareholder report
- SCHEDULE 13G/A Major shareholder report (passive investor)
Prospectus 56
- S-3 Registration statement for specified transactions by certain issuers
- 424B3 Prospectus filed pursuant to Rule 424(b)(3)
- 424B4 Prospectus filed pursuant to Rule 424(b)(4)
- S-1/A General form of registration statement for all companies including face-amount certificate companies
- S-1 General form of registration statement for all companies including face-amount certificate companies
- 424B3 Prospectus filed pursuant to Rule 424(b)(3)
- S-3 Registration statement for specified transactions by certain issuers
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Proxies 26
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
Other 52
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
- UPLOAD Letter (PDF)
- EFFECT Notice of Effectiveness
- EFFECT Notice of Effectiveness
- POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
- POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
- EFFECT Notice of Effectiveness